Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Micafungin Sodium"'
Publikováno v:
Hospital Pharmacy. 53:125-127
Purpose: The purpose of this study was to determine the physical compatibility of micafungin with commonly used concentrations of sodium bicarbonate hydration fluids administered via a Y-site connected to a central venous catheter (Y-site/CVC). Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5720d6e86a33d719625f5c8785687c26
https://doi.org/10.1177/0018578717738391
https://doi.org/10.1177/0018578717738391
Publikováno v:
International Journal of Molecular Sciences
Volume 14
Issue 11
Pages 21202-21214
International Journal of Molecular Sciences, Vol 14, Iss 11, Pp 21202-21214 (2013)
Volume 14
Issue 11
Pages 21202-21214
International Journal of Molecular Sciences, Vol 14, Iss 11, Pp 21202-21214 (2013)
An isocratic, sensitive and stability-indicating high performance liquid chromatographic (HPLC) method for separation and determination of the related substances of micafungin sodium was developed. The chromatographic separation was achieved on Agile
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7410d089a8532a03554c95947cbde841
https://doi.org/10.3390/ijms141121202
https://doi.org/10.3390/ijms141121202
Publikováno v:
Mycoses. 55:e60-e73
The opportunistic yeast pathogen Candida albicans and the emerging non-albicans Candida spp. cause life-threatening infections in immuno-compromised patients, leading to an increase in mortality rate. At present, the emergence of non-albicans Candida
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be68e9a04c1120ac60e5610672e13e76
https://doi.org/10.1111/j.1439-0507.2011.02156.x
https://doi.org/10.1111/j.1439-0507.2011.02156.x
Publikováno v:
International Journal of Pharmaceutics
International Journal of Pharmaceutics, Elsevier, 2015, 492, pp.137-40. ⟨10.1016/j.ijpharm.2015.07.019⟩
International Journal of Pharmaceutics, Elsevier, 2015, 492, pp.137-40. ⟨10.1016/j.ijpharm.2015.07.019⟩
International audience; Micafungin is a costly treatment and packaging of 50mg or 100mg bottles only are available, while doses lower than 5mg and 20mg are often necessary in neonates and paediatrics patients, respectively. The stability of micafungi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b6c1e48b4dab54a0cc2cb7f62941769
https://hal.archives-ouvertes.fr/hal-01392457
https://hal.archives-ouvertes.fr/hal-01392457
Autor:
Bianca Maria Goffredo, Imma Savarese, Cinzia Auriti, Fiammetta Piersigilli, Giuseppe Bianco, Andrea Dotta, Iliana Bersani
Publikováno v:
The Pediatric infectious disease journal. 33(4)
So-called lock therapy, consisting of high concentrations of antimicrobials instilled into the lumen of the catheter, has been suggested avoid central venous catheter removal during fungal infection. We report a baby who developed catheter-related ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d30c128eda4acfac4b6b8cacfeddb5b5
https://pubmed.ncbi.nlm.nih.gov/24637514
https://pubmed.ncbi.nlm.nih.gov/24637514
Publikováno v:
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 68(23)
Purpose The physical compatibility of telavancin with select i.v. drugs during simulated Y-site administration was evaluated. Methods Telavancin for injection was reconstituted according to manufacturer’s recommendations and diluted with 0.9% sodiu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a33eca262e4244bc7a7df5c5552d1802
https://pubmed.ncbi.nlm.nih.gov/22095816
https://pubmed.ncbi.nlm.nih.gov/22095816
Pharmaceutical aerosols have been targeted to the lungs for the treatment of asthma and pulmonary infectious diseases successfully. Micafungin (Astellas Pharma US, Deerfield, IL, USA) has been shown to be an effective antifungal agent when administra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f9e5265ff10848f7b9489b5fe3288b8
https://europepmc.org/articles/PMC2663675/
https://europepmc.org/articles/PMC2663675/
Publikováno v:
Clinical therapeutics. 30(5)
Background: Micafungin sodium is indicated for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation (HSCT). One Phase III, multi-institutional, randomized, doubleblind comparative trial involving 882 ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2fb1a1fda117f79dc49b09a8caf15a9
https://pubmed.ncbi.nlm.nih.gov/18555943
https://pubmed.ncbi.nlm.nih.gov/18555943
Autor:
Oliver A. Cornely, Jörg J. Vehreschild
Publikováno v:
Future microbiology. 1(2)
Micafungin is a new drug in the echinocandin class and is currently being investigated in Phase III clinical trials. Like other echinocandins, it inhibits 1,3-β-D-glucan synthesis, thus achieving fungicidal activity against virtually all Candida spp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1029b247167515d29c53306124f049c3
https://pubmed.ncbi.nlm.nih.gov/17661660
https://pubmed.ncbi.nlm.nih.gov/17661660
Autor:
Mitsuyoshi Utsugi, Masatomo Mori, Ken Sato, Takahiro Ishizuka, Minoru Hayashi, Hitoshi Takagi
Publikováno v:
Clinical therapeutics. 29(7)
A 73-year-old man (height, 158.2 cm; weight, 49.8 kg) presented with upper abdominal tenderness after 3 weeks of treatment with 150 mg/d of micafungin (3 mg/kg . d) (Mycamine, Astellas Pharma US Inc., Deerfield, Illinois) intravenously for pulmonary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fd639cbd58f7e82fa00bffda56dbec7
https://pubmed.ncbi.nlm.nih.gov/17825698
https://pubmed.ncbi.nlm.nih.gov/17825698